FULC Stock Forecast & Price Target

Fulcrum Therapeutics is facing concerns from the FDA due to the potential risk of malignancies associated with PRC2 inhibitors like their product candidate, pociredir, despite presenting data showing differences in mechanism and potential lower risk in targeting EED rather than EZH2. This has led to a firm stance from the FDA on the entire class of PRC2 inhibitors, potentially impacting the future of Fulcrum's development plans and its overall valuation as it undergoes strategic review and restructuring. Its current market value per share of $4 reflects the market's uncertainty about the company's future success and the impact of the FDA's position.

Fulcrum Therapeutics is facing clinical, regulatory, and financial risks that could negatively impact its stock, despite having an experienced management team and a promising pipeline of therapies for rare diseases. The FDA recently discontinued development of the company's lead product candidate, Pociredir, due to concerns about potential long-term malignancy risk. These setbacks have led to a downgrade of the company's rating to "Underweight" and a decrease in its price target to $3 from $23, based on projected cash reserves in mid-2027.